NetworkNewsAudio – The Next Generation of the GLP-1 Revolution Is Already Underway
This audio news release has been disseminated on behalf of SureNano Science and may include a paid advertisement. Related Editorial Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (Profile) through…







